Travere Therapeutics Inc.

7 days ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. F.

10 days ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO.“These biomarker data provide new insight into how FILSPARI's dual mechanism of action may modify the unde.

11 days ago · zacks.com

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)."The final SPARTAN analysis provides a compelling picture of what's possible whe.

1 month ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain me.

1 month ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and.

2 months ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.About Travere TherapeuticsAt Travere Therapeutics, we are in rare.

3 months ago · seekingalpha.com

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.

3 months ago · marketbeat.com

Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.

3 months ago · seekingalpha.com

Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risks and valuation concerns. Filspari's Q2 net sales surged 96% YoY to $141M, but $3B+ peak sales guidance faces new competition in IgAN and FSGS markets. TVTX's pipeline expansion with civorebrutinib and pegtibatinase targets rare kidney and metabolic diseases, but both remain early-stage with uncertain timelines.